Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 10/20 | 0.41 |
| ▸ | TDO2 | P48775 | 4/20 | 0.41 |
| ▸ | IDO2 | Q6ZQW0 | 4/20 | 0.41 |
| ▸ | IDO1 | P14902 | 3/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24089965 | 0.94 | HTR7 (0.42) | HTR7TDO2IDO2IDO1P2RX3 | |
| SCHEMBL24089899 | 0.93 | HTR7 (0.41) | HTR7TDO2IDO2IDO1P2RX3 | |
| SCHEMBL23045335 | 0.91 | NPC1 (0.40) | — | |
| SCHEMBL29623066 | 0.91 | NPC1 (0.40) | — | |
| SCHEMBL24089967 | 0.89 | TDO2 (0.41) | HTR7TDO2IDO2IDO1P2RX3 | |
| SCHEMBL23065101 | 0.89 | MEN1 (0.48) | HTR7TDO2IDO2IDO1KCNH2 | |
| SCHEMBL23065098 | 0.88 | MEN1 (0.52) | HTR7TDO2IDO2IDO1KCNH2 | |
| SCHEMBL29623188 | 0.88 | MEN1 (0.52) | HTR7TDO2IDO2IDO1KCNH2 | |
| SCHEMBL23065077 | 0.86 | HTR7 (0.42) | HTR7TDO2IDO2IDO1 | |
| SCHEMBL23065082 | 0.86 | IDO1 (0.55) | HTR7TDO2IDO2IDO1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114650986-A | 2-aminoquinazolinone derivatives | 住友制药株式会社 | 2022-06-21 | — | — | CN | claimed |
| CN-114650986-A | 2-aminoquinazolinone derivatives | 住友制药株式会社 | 2022-06-21 | — | — | CN | disclosed |
| US-11352366-B2 | 2-aminoquinazolinone derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-06-07 | — | — | US | disclosed |
| US-20220143020-A1 | 2-AMINOQUINAZOLINONE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-05-12 | — | — | US | disclosed |
| US-20210380598-A1 | 2-AMINOQUINAZOLINONE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2021-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220143020-A1 | 2-AMINOQUINAZOLINONE DERIVATIVE | CNKSR1, HAX1, CRKL | HTR7 1340/4885TDO2 2059/4885IDO2 398/4885 |
| US-20210380598-A1 | 2-AMINOQUINAZOLINONE DERIVATIVE | CNKSR1, HAX1, SLC26A3 | HTR7 1046/4885TDO2 1774/4885IDO2 416/4885 |
| US-11352366-B2 | 2-aminoquinazolinone derivative | CNKSR1, HAX1, SLC26A3 | HTR7 1046/4885TDO2 1774/4885IDO2 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.